<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="app1table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.38200.020</object-id><label>Appendix 1&#8212;table 1.</label><caption><title>Main characteristics of patients from cohorts 1 and 2 in Karakalpakstan, Uzbekistan.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">Cohort 1</th><th valign="top">Cohort 2</th><th valign="top">P value</th></tr></thead><tbody><tr><td valign="top">Year of isolate collection <break/>(patient diagnosis with MDR-TB)</td><td valign="top">2001&#8211;2002</td><td valign="top">2003&#8211;2006</td><td valign="top"/></tr><tr><td valign="top">No. MDR cases diagnosed within time period</td><td valign="top">57</td><td valign="top">300</td><td valign="top"/></tr><tr><td valign="top">No. Included in this analysis <break/>Reasons for non-inclusion: <break/>Multiple strain infection <break/>No DNA available <break/>Patient already in cohort 1 <break/>Low DNA quantity</td><td valign="top">49 (86%) <break/>6 <break/>2 <break/>NA <break/>0</td><td valign="top">228 (76%) <break/>1 <break/>40 <break/>11 <break/>20</td><td valign="top">0.094</td></tr><tr><td valign="top">Patient residence (within Karakalpakstan) <break/>Nukus <break/>Chimbay <break/>Other <break/>Unknown</td><td valign="top">34 (69%) <break/>6 <break/>9 <break/>0</td><td valign="top">146 (64%) <break/>64 <break/>1 <break/>17</td><td valign="top">0.49</td></tr><tr><td valign="top">Male</td><td valign="top">27 (55%)</td><td valign="top">119 (52%)</td><td valign="top">0.72</td></tr><tr><td valign="top">Age (median, IQR) <break/>Missing age</td><td valign="top">32, 27&#8211;38 <break/>0</td><td valign="top">31, 24&#8211;41 <break/>49 (21%)</td><td valign="top">0.40</td></tr><tr><td valign="top">Previous TB treatment</td><td valign="top">38 (78%)</td><td valign="top">228 (100%)</td><td valign="top">&lt;0.0001</td></tr><tr><td valign="top">First-line resistance profile: <break/>HR <break/>HRE <break/>HRS <break/>HRES <break/>HRSZ <break/>HREZ <break/>HRESZ</td><td valign="top">1 <break/>0 <break/>12 (24%) <break/>28 (57%) <break/>1 (2%) <break/>1 <break/>7 (14%)</td><td valign="top">2 <break/>1 <break/>41 (18%) <break/>49 (21%) <break/>27 (12%) <break/>1 <break/>107 (47%)</td><td valign="top">&lt;0.0001</td></tr><tr><td valign="top">No. of first-line drugs resistant <break/>2 <break/>3 <break/>4 <break/>5</td><td valign="top">1 <break/>12 (24%) <break/>30 (61%) <break/>7 (14%)</td><td valign="top">2 <break/>42 (18%) <break/>77 (34%) <break/>107 (47%)</td><td valign="top">&lt;0.0001</td></tr><tr><td valign="top">Availability of second-line drug susceptibility testing (DST)</td><td valign="top">Ofx, Cap, Proth</td><td valign="top">Ofx, Cap, Ami, Eth, Cyc, PAS</td><td valign="top"/></tr><tr><td valign="top">Ofx resistance</td><td valign="top">5 (10%)</td><td valign="top">6 (3%)</td><td valign="top">0.033</td></tr><tr><td valign="top">Cm resistance</td><td valign="top">1 (2%)</td><td valign="top">53 (23%)</td><td valign="top">0.0001</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: H&#160;=&#160;isoniziad, R&#160;=&#160;rifampicin, E&#160;=&#160;ethambutol, S&#160;=&#160;streptomycin, Z&#160;=&#160;pyrazinamide, Ofx&#160;=&#160;ofloxacin, Cm&#160;=&#160;capreomycin</p></fn></table-wrap-foot></table-wrap>